A) Zyprexa B) Risperdal C) Prolixin D) Geodon
A) Clozaril B) Zyprexa C) Invega D) Abilify
A) Invega B) Seroquel C) Zyprexa D) Abilify
A) Abilify B) Seroquel C) Zyprexa D) Risperdal
A) Seroquel B) Abilify C) Risperdal D) Geodon
A) Clozapine B) Ziprasidone C) Quetiapine D) Olanzapine
A) Risperidone B) Aripriprazole C) Ziprasidone D) Paliperidone
A) Clozaril B) Seroquel C) Geodon D) Risperdal
A) Aripiprazole B) Ziprasidone C) Paliperidone D) Clozapine
A) Risperdone B) Paliperidone C) Quetiapine D) Olazapine
A) Risperidone and Paliperidone B) Aripiprazole and Paliperidone C) Clozapine and Aripiprazole D) Clozapine and Risperadone
A) 4-5 B) 1-3 C) 1 D) 2-5
A) 12 B) 18 C) 6 D) 24
A) TRUE B) FALSE
A) Minimize side effects of medication B) Develop more adaptive coping skills C) Foster patients' medication compliance D) Prevent relapse into another psychotic episode
A) several weeks after discontinuation of medication B) one year after discontinuation of medication C) directly after discontinuation of medication D) six months after discontinuation of medication
A) Clozaril B) Thorazine C) Artane D) Symmetrel
A) enhanced efficacy in treatment-resistant patients B) tardive dyskinesia more common C) weight gain more common D) increased effectiveness for positive, negative, and disorganized symptoms
A) Risperidone B) Clozapine C) Haloperiodol D) Prochlorperazine
A) Anticonvulsants B) Stimulants C) Anxiolitics D) Alcohol
A) Beta blockers B) Alcohol C) Merperidine D) Halperiodol
A) Beta blockers B) Antacids C) Anticonvulsants D) Nicotine
A) Beta blockers B) Alcohol C) Tricyclic antidepressants D) SSRIs
A) FALSE B) TRUE
A) Male gender B) Drug holidays C) Alcohol use D) Tobacco use
A) TRUE B) FALSE
A) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. B) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia. C) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. D) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications.
A) Akathesia B) Akinesia C) Acute dystonia D) Ataxia
A) Neuroleptic Malignant Syndrome B) Agranulocytosis C) Postural hypotension D) Gynecomastia
A) FALSE B) TRUE
A) FALSE B) TRUE
A) agonize the normal dopamine-mediated inhibition of prolactin release. B) antagonize the normal dopamine-mediated inhibition of prolactin release. C) block D2 receptors in the pituitary gland and decrease prolactin secretion. D) block D2 receptors in the pituitary gland and inhibit prolactin secretion.
A) hungry hungry hippos B) neuroendocrine changes C) receptor binding and DA turnover D) molecular structure
A) Thioxanthenenes B) Sleepykoaladones C) Phenothiazines D) Butyrophenones
A) Potent; low; lower B) Weak; high; higher C) Potent; low; higher D) Weak; high; lower
A) Formal thought disorder B) Delusions C) Anhedonia D) Hallucinations
A) Autoimmune diseases B) All of the above C) Endocrine disorders D) Neurological disorders E) Metabolic disorders
A) Hallucinogens B) All of the above C) Opioids D) Alcohol E) Stimulants
A) TRUE B) FALSE
A) positive symptoms of Schizophrenia. B) negative symptoms of Schizophrenia. C) All of the above. D) disorganized symptoms of Schizophrenia.
A) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. D) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine.
A) increased release of dopamine B) increased rates of synthesis C) increased rates of firing D) increased tap dancing
A) aliphatics B) thioxanthenes C) piperideines D) piperazines
A) all of the above B) menstrual irregularity C) galactorrhea D) genecomastia
A) Artane (trihexphenidyl) B) Inapsine (droperiodol) C) Symmetrel (amantadine) D) Benadryl (diphenhydramine) E) Cogentin (benztropine)
A) FALSE B) TRUE
A) actual impact at the biological level B) comparative lack of EPS C) polypharmacy D) superior impact on positive symptoms
A) Invega B) Clozaril C) Haldol D) Abilify
A) Seroquel B) Geodon C) Risperdal D) Clorazil |